

## Lilly Cares® Foundation 2019 State-Level Results

### Diabetes Medications

BAQSIMI™ (glucagon) nasal powder; Basaglar® (insulin glargine injection); Glucagon (glucagon for injection [rDNA origin]); Humalog® (insulin lispro injection); Humulin® (human insulin [rDNA origin]); Trulicity® (dulaglutide)

	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$ 140,000	24
AL	\$ 12,700,000	2107
AR	\$ 2,300,000	359
AZ	\$ 3,200,000	482
CA	\$ 9,620,000	1556
CO	\$ 2,000,000	293
CT	\$ 1,100,000	170
DC	\$ 54,000	12
DE	\$ 950,000	137
FL	\$ 30,000,000	5098
GA	\$ 26,200,000	3997
HI	\$ 100,000	15
IA	\$ 2,000,000	284
ID	\$ 5,200,000	737
IL	\$ 9,080,000	1273
IN	\$ 15,900,000	2122
KS	\$ 9,400,000	1434
KY	\$ 5,800,000	841
LA	\$ 4,900,000	838
MA	\$ 1,860,000	244
MD	\$ 3,400,000	498
ME	\$ 3,100,000	490
MI	\$ 9,500,000	1353
MN	\$ 3,100,000	464
MO	\$ 16,300,000	2470
MS	\$ 5,710,000	914
MT	\$ 800,000	143
NC	\$ 34,300,000	5237
ND	\$ 550,000	97
NE	\$ 6,200,000	964
NH	\$ 1,800,000	245
NJ	\$ 4,500,000	690
NM	\$ 690,000	112
NV	\$ 1,300,000	197
NY	\$ 6,140,000	885
OH	\$ 20,000,000	2858
OK	\$ 7,600,000	1264
OR	\$ 4,000,000	513
PA	\$ 13,700,000	2007
PR	\$ 100,000	14
RI	\$ 1,250,000	169
SC	\$ 7,700,000	1223
SD	\$ 1,300,000	197
TN	\$ 17,400,000	2408
TX	\$ 61,300,000	9625
UT	\$ 5,800,000	828
VA	\$ 20,600,000	3616
VT	\$ 90,000	19
WA	\$ 3,000,000	434
WI	\$ 6,300,000	898
WV	\$ 3,000,000	418
WY	\$ 1,200,000	193

BAQSIMI™ is a trademark and Basaglar®, Humalog®, Humulin®, and Trulicity® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

### Mental Health Medications

Cymbalta® (duloxetine delayed-release capsules); Prozac® (fluoxetine); Strattera® (atomoxetine); Symbyx® (olanzapine and fluoxetine); Zyprexa® (olanzapine)

	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$ 17,000	6
AL	\$ 5,710,000	1366
AR	\$ 330,000	77
AZ	\$ 84,000	29
CA	\$ 420,000	108
CO	\$ 220,000	45
CT	\$ 40,000	7
DE	\$ 25,000	8
FL	\$ 10,000,000	2738
GA	\$ 15,400,000	3266
HI	\$ 6,000	2
IA	\$ 72,000	24
ID	\$ 4,480,000	805
IL	\$ 340,000	92
IN	\$ 1,270,000	320
KS	\$ 4,500,000	970
KY	\$ 340,000	99
LA	\$ 380,000	125
MA	\$ 27,000	12
MD	\$ 250,000	68
ME	\$ 1,160,000	265
MI	\$ 410,000	124
MN	\$ 130,000	39
MO	\$ 4,500,000	993
MS	\$ 1,730,000	439
MT	\$ 260,000	65
NC	\$ 16,400,000	3464
ND	\$ 120,000	24
NE	\$ 3,510,000	733
NH	\$ 150,000	37
NJ	\$ 230,000	47
NM	\$ 48,000	8
NV	\$ 20,000	8
NY	\$ 290,000	62
OH	\$ 870,000	267
OK	\$ 19,600,000	4080
OR	\$ 230,000	54
PA	\$ 850,000	218
RI	\$ 31,000	8
SC	\$ 2,270,000	479
SD	\$ 2,770,000	538
TN	\$ 5,600,000	1184
TX	\$ 69,500,000	14183
UT	\$ 620,000	140
VA	\$ 8,300,000	1990
VT	\$ 8,000	2
WA	\$ 140,000	38
WI	\$ 540,000	105
WV	\$ 260,000	80
WY	\$ 1,070,000	239

Cymbalta®, Prozac®, Strattera®, Symbyx®, and Zyprexa® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

### Cancer Medications

Alimta® (pemetrexed for injection); Cyramza® (ramucirumab); Erbitux® (cetuximab); Lartruvo® (olaratumab); Portrazza® (necitumumab); Verzenio® (abemaciclib)

	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AL	\$ 2,900,000	96
AR	\$ 1,800,000	50
AZ	\$ 3,400,000	76
CA	\$ 6,700,000	130
CO	\$ 1,410,000	28
CT	\$ 930,000	15
DC	\$ 75,000	2
DE	\$ 440,000	6
FL	\$ 15,400,000	379
GA	\$ 5,660,000	123
HI	\$ 110,000	4
IA	\$ 1,400,000	23
ID	\$ 1,200,000	20
IL	\$ 3,200,000	75
IN	\$ 2,700,000	65
KS	\$ 1,500,000	38
KY	\$ 2,300,000	38
LA	\$ 1,350,000	32
MA	\$ 2,100,000	31
MD	\$ 1,400,000	34
ME	\$ 550,000	14
MI	\$ 3,200,000	58
MN	\$ 1,300,000	22
MO	\$ 2,900,000	66
MS	\$ 2,000,000	43
MT	\$ 250,000	5
NC	\$ 5,000,000	129
ND	\$ 420,000	7
NE	\$ 780,000	18
NH	\$ 150,000	3
NJ	\$ 5,400,000	104
NM	\$ 280,000	7
NV	\$ 1,860,000	32
NY	\$ 5,100,000	100
OH	\$ 4,000,000	106
OK	\$ 2,700,000	64
OR	\$ 2,100,000	40
PA	\$ 4,800,000	102
PR	\$ 40,000	2
RI	\$ 100,000	2
SC	\$ 2,300,000	69
SD	\$ 170,000	5
TN	\$ 3,800,000	105
TX	\$ 16,000,000	395
UT	\$ 720,000	10
VA	\$ 4,100,000	91
VT	\$ 280,000	8
WA	\$ 1,600,000	35
WI	\$ 1,700,000	28
WV	\$ 540,000	20
WY	\$ 35,000	1

Alimta®, Cyramza®, Erbitux®, Lartruvo®, Portrazza®, and Verzenio® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

### Other Medications

Cialis® (tadalafil); Emgality® (galcanezumab-gnlm) injection; Evista® (raloxifene hydrochloride); Forteo® (teriparatide [rDNA origin] injection); Humatrope® (somatropin) for injection; Olumiant® (baricitinib) tablets; Taltz® (ixekizumab) injection

	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$ 820,000	24
AL	\$ 10,030,000	509
AR	\$ 9,590,000	274
AZ	\$ 8,880,000	324
CA	\$ 26,700,000	980
CO	\$ 9,350,000	316
CT	\$ 2,940,000	95
DC	\$ 140,000	5
DE	\$ 1,910,000	64
FL	\$ 55,700,000	3368
GA	\$ 19,800,000	882
HI	\$ 1,080,000	33
IA	\$ 4,980,000	185
ID	\$ 4,390,000	187
IL	\$ 17,500,000	603
IN	\$ 16,600,000	585
KS	\$ 7,400,000	284
KY	\$ 8,140,000	299
LA	\$ 10,400,000	370
MA	\$ 6,150,000	181
MD	\$ 4,500,000	164
ME	\$ 1,500,000	86
MI	\$ 15,100,000	546
MN	\$ 6,820,000	225
MO	\$ 15,000,000	671
MS	\$ 6,400,000	371
MT	\$ 1,480,000	65
NC	\$ 22,300,000	992
ND	\$ 2,290,000	84
NE	\$ 2,260,000	105
NH	\$ 1,760,000	62
NJ	\$ 10,400,000	323
NM	\$ 1,510,000	55
NV	\$ 3,520,000	106
NY	\$ 12,800,000	462
OH	\$ 18,500,000	653
OK	\$ 11,900,000	431
OR	\$ 5,000,000	157
PA	\$ 18,400,000	618
PR	\$ 1,160,000	48
RI	\$ 920,000	38
SC	\$ 8,540,000	366
SD	\$ 1,830,000	76
TN	\$ 14,900,000	631
TX	\$ 49,600,000	2067
UT	\$ 4,430,000	180
VA	\$ 12,100,000	596
VT	\$ 450,000	19
WA	\$ 8,770,000	281
WI	\$ 7,840,000	296
WV	\$ 2,400,000	88
WY	\$ 390,000	24

Cialis®, Emgality®, Evista®, Forteo®, Humatrope®, Olumiant®, and Taltz® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares Foundation, Inc., Lilly Corporate Center, Indianapolis, IN 46285; Steve Stapleton, President, [stapleton.steven\\_j@lilly.com](mailto:stapleton.steven_j@lilly.com)